Sections

sections button arrow
2025 AACR grant recipients

Research and Grants Administration

tooltip iconAACR grant recipients were acknowledged during a special reception at the AACR Annual Meeting 2025.

Investing in Innovation

The AACR grants program has distributed more than $551 million in grants to more than 3,500 researchers at all career levels since 1993. This critical funding sustains the pipeline of progress and drives innovation across the continuum of basic, translational, and clinical research to benefit all patients with cancer.

NEW GRANTS, NEW PARTNERS, BOLD NEW INITIATIVES

AACR’s grant portfolio expanded significantly in 2025 with a host of new supporters and new funding mechanisms:

  • AACR Trailblazer Cancer Research Grants for Early-Stage and Mid-Career Investigators. At the AACR Annual Meeting in April, AACR announced the launch of its largest-ever grant program. Developed to address the funding challenges facing the cancer research community, the Trailblazer Cancer Research Grants will provide $1 million over three years to nine early-stage investigators and six mid-career investigators. This unprecedented $15 million investment from AACR will fund paradigm-shifting research projects that advance the understanding of cancer biology, drive groundbreaking translational science, and improve patient outcomes. The recipients of these pioneering grants will be announced at the AACR Annual Meeting 2026.
  • AACR Hematologic Malignancies Research Fellowship. Powered by the generous contribution of an anonymous donor, AACR awarded its first-ever fellowship focused exclusively on hematologic malignancies in 2025. This new grant supports a postdoctoral or clinical research fellow pursuing innovative research in basic, translational, clinical, or population sciences related to blood cancers.
  • AACR Grants for Innovative Bladder Cancer Research. Thanks to the generous support of another anonymous donor, AACR also offered its first-ever grant to support the development of novel approaches to bladder cancer treatment. These grants—which were presented to two investigators in 2025—fund translational and clinical research projects to improve outcomes for bladder cancer patients.
  • AACR-ALK Positive Lung Cancer Research Fellowship. AACR welcomed ALK Positive—a patient-driven organization that seeks a cure for ALK-positive cancer and works to improve quality of life and life expectancy for patients worldwide—as a new funding partner in 2025. The fellowship supports a postdoctoral or clinical research fellow conducting research that directly benefits ALK-positive cancer patients.
  • AACR-EMD Serono “I’M IN” Oncodisparity Fellowships in Lung and Urothelial Cancers. EMD Serono also became an AACR grant supporter for the first time in 2025. This new fellowship supports early-career researchers working to reduce inequalities in lung and urothelial cancer care by improving patient outcomes in underserved communities.
  • AACR-Swim Across America Pediatric Cancer Research Fellowship. This new fellowship from a previous AACR grant funder is dedicated to improving outcomes for children with cancer.
  • AACR-Hope Scarves Metastatic Breast Cancer Innovation and Discovery Grant. In 2025, AACR launched a new partnership with Hope Scarves—a nonprofit that supports people living with all types of cancer—to support research projects that translate innovative ideas into treatment strategies for metastatic breast cancer.
  • AACR-Ocular Melanoma Foundation Miriam Counts Innovation and Discovery Grants. The Ocular Melanoma Foundation is a long-standing supporter of AACR grants. This new funding mechanism is designed to stimulate creative approaches to translate basic research into new treatment options for ocular/uveal melanoma.
Shawn H.R. Lee, MD, PhD, AACR Grantee

53

Grants were awarded in 2025 to meritorious scientists from 39 institutions to support innovative cancer science.

507

Expert scientists served on 20 scientific review committees to select the 2025 grant recipients. AACR is a trusted administrator of research grants, providing fair, rigorous, and transparent peer review.

$9.7 million

Amount awarded to 60 independent investigators at all career levels—including young investigators, mid-career researchers, and established scientists—to support meritorious cancer research.

$1.8 million

Amount of research grant funding awarded to 16 postdoctoral and clinical fellows to advance their career development in 2025.

1,396

Applications for AACR grants from the United States and 63 other countries were evaluated in 2025.

AACR and Stand Up To Cancer: A Partnership for Patients

A supporting organization to the Entertainment Industry Foundation, Stand Up To Cancer (SU2C) supports collaboration and innovation in translational cancer science to accelerate the development of new cancer treatments. As the Scientific Partner to SU2C, AACR provides expert peer review, scientific oversight, and grants administration to ensure that SU2C’s investment in groundbreaking cancer science delivers outstanding results for patients.

SU2C TELECAST: RAISING AWARENESS AND FUNDS FOR CANCER RESEARCH

On August 15, with the support of the AACR, SU2C produced its ninth biennial telecast. The telecast featured powerful performances by celebrities and musicians as well as touching patient stories. It aired on twenty-two networks and streaming partners, including all four broadcasting networks and over thirty streaming partners, such as Prime Video, MAX, Hulu, Peacock, and Paramount+.

ADDRESSING CANCER HEALTH DISPARITIES

During the 18th AACR Conference on The Science of Cancer Health Disparities in September, AACR and SU2C held a special session on Advances in Clinical Trial Access and Community Engagement. SU2C Scientific Advisory Committee Chair William G. Nelson, MD, PhD, chaired the session, which highlighted progress against cancer disparities driven by SU2C support.

Stand Up To Cancer Telecast, August 15, 2025

ADDRESSING CANCER HEALTH DISPARITIES

During the 18th AACR Conference on The Science of Cancer Health Disparities in September, AACR and SU2C held a special session on Advances in Clinical Trial Access and Community Engagement. SU2C Scientific Advisory Committee Chair William G. Nelson, MD, PhD, chaired the session, which highlighted progress against cancer disparities driven by SU2C support.

arrow to previous page Science and Education

Science and Education

Policy and Advocacy

arrow to next page Policy and Advocacy